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Abstract 
Everolimus (EV), a rapamycin analogue mTOR inhibitor, is used in the clinic to treat 
Estrogen positive (ER
+
) breast cancer in order to avoid the resistance to hormonotherapy. 
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Here, we investigated whether EV efficacy varied according to administration timing by using 
the ER
+ 
breast cancer cell line MCF-7 as model system.  Our results showed that instead of 
apoptosis, EV induced a G0/G1 phase blockage of MCF-7 cells. Following serum shock, 
MCF-7 cells displayed a statistically significant 24h rhythm of mammalian target of 
Rapamycin (mTOR) activity, but perturbed circadian clock genes oscillations. Interestingly, 
the different delivery schedule of EV presented different efficacy in G0/G1 phase blockage in 
serum shocked MCF-7 cells. Moreover, serum shock induced also a circadian-like oscillation 
in expression or activity of several important G1 phase progression proteins, such as Cyclin 
D1 and phosphorylated Retinoblastoma protein (RB). Inhibition mTOR activity by EV 
reduced Cyclin D1 and Cyclin D3 protein level as well as RB phosphorylation level. Taken 
together, the results indicated that serum shock synchronization induced a circadian 
oscillation in mTOR activity in MCF-7 cells, which rhythmically regulated the synthesis or 
phosphorylation of key G1 progression proteins, such as Cyclin D1 and phosphorylated RB, 
ultimately resulting in different G0/G1 blockage efficiency according to different EV 
administration timing. 
Introduction: 
Breast cancer is the most invasive female cancer, accounting for 25% of all cancers in women 
and resulting in 1.68 million cases and 522,000 deaths worldwide in 2012.
1
 Nearly 70% of 
breast cancers express estrogen-receptors (ER
+
) and hence benefit from anti-estrogen 
therapies. Recent therapeutic progress has led to combine anti-estrogens with Everolimus 
(EV), an inhibitor of the mammalian target of rapamycin (mTOR) pathway/signaling, in order 
to avoid or reduce resistance to estrogen receptor targeted drugs.
2-6
  
The mTOR is a serine/threonine protein kinase in the phosphatidylinositol 3-kinase-related 
kinase protein family. mTOR participates at least the formation of two distinct multi-protein 
complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2),  which play 
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important roles in cell growth, cell proliferation, metabolism and survival. EV binds to its 
protein receptor FK506 binding protein 12 (FKBP12) to form a complex, which inhibits the 
activity of mTORC1.  One of the most important roles of mTORC1 is to promote protein 
synthesis by phosphorylating the eukaryotic initiation factor 4E (eIF4E)-binding protein 1 
(4E-BP1) and the p70 ribosomal S6 kinase 1 (S6K1). The phosphorylation of 4E-BP1 inhibits 
the interaction between 4E-BP1 and eIF4E, finally promotes cap-dependent translation. The 
phosphorylation of S6K1 by mTORC1 increases mRNA biogenesis, promotes cap-dependent 
translation and elongation, and the translation of ribosomal proteins etc..
7-9 
mTOR signaling is 
commonly deregulated in most human cancers. Hence, it is considered as a target for anti-
cancer treatments, especially for kidney and neuroendocrine malignancies, as well as ER
+
 
breast cancers.
2-9
 
 
Furthermore, mTOR activity displays a circadian (about 24 hours) variation in different 
mouse tissues and cells, including heart, liver, spleen, adipose tissue and brain (as cerebellum, 
frontal cortex and suprachiasmatic nucleus) etc., as well as in primary lung fibroblasts and 
renal carcinoma cell RenCa etc..
10-15
 Circadian cycles exist in most living organisms and 
coordinate organismal behavior, physiology and metabolism with environmental cycles 
during the course of every 24 hours. In mammals, circadian rhythms are systemically 
coordinated by the hypothalamic suprachiasmatic nuclei.
16
 At cellular level, circadian rhythm 
is generated through interwoven transcription and translation feedback loops, involving about 
15 clock genes and proteins, including the core molecular Bmal1, Clock, Cryptochromes 
(Cry1 and Cry2), Periods (Per1, Per2 and Per3) etc..
17
 In brief, the transcriptional activator 
complex of Bmal1/Clock or Bmal1/Npas2 activates the transcription of their targets Cry1, 
Cry2, Per1, Per2 and Per3, these Cry and Per proteins in turn repress their own transcription 
through their interactions with the Clock-Bmal1 heterodimer. The Bmal1/Clock heterodimer 
also activates the transcription of clock genes Rev-Erb α/β and Ror α/β/γ, which respectively 
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repress and activate Bmal1 transcription.
17
 Such rhythmical genetic circadian clock results 
that about 3%-10% of genes show one rhythmic expression, which are involved in major cells 
activity, as proliferation, metabolism, senescence, apoptosis and DNA damage response 
etc..
18-20  
These circadian rhythms can further modify both tolerability and efficacy of drugs, resulting 
in dosing time-dependent pharmacology and effects. Recent experimental data using target 
anticancer agents have demonstrated the importance of dosing time as well as drug dose in 
pharmacological effects determination.
18-20
 Clinical trials have further shown that the 
circadian timing of chrono-modulated chemotherapy could improve tolerability up to 5-fold 
and nearly double efficacy as compared to constant rate or oppositely-timed infusions.
19
 
Preliminary clinical data with EV indeed suggested that morning oral dosing could reduce 
side-effects in patients with metastatic breast cancers.
21
 Moreover, in corresponding to 
circadian activation of mTOR in RenCa tumor mass,  EV dosing time influence the survival 
rate of RenCa-bearing mice.
14 
All these findings led us to investigate EV efficacy according to 
dosing-time in synchronized human MCF-7 cell cultures, as a model of  ER
+
 human breast 
cancer.  
Materials and methods 
Cell culture and serum shock synchronization 
MCF-7(ATCC® HTB-22™, LGC Standards SARL, France) cells were grown in Dulbecco’s 
modified Eagle medium (DMEM) supplemented with GlutaMAX (GIBCO, Life Technology, 
CA, USA) and 10% fetal bovine serum (FBS, Hyclone, UT, USA). MCF-10A (ATCC® 
CRL-10317™, LGC Standards SARL, France) cells were cultured as previously described.20 
For western-blot, qRT-PCR and flow cytometry analysis, MCF-7 cells were seeded into 6-
well plates, allowed to reach 15%-20% confluence in exponential growth phase and then 
synchronized with a serum shock as previously described.
22-23
 Subsequently, the cells were 
5 
 
returned to their usual culture condition and collected at indicated times. The first sample 
(Time 0: T0) was taken just after the serum shock completion. During bioluminescence 
recordings, cells were cultured in phenol red-free media supplemented 1mM luciferin 
(Promega, WI, USA). For these recordings, MCF-7 and MCF-10A cultures were tested with 
starting confluence of 10-15%, 20-25% or 30-40% and recorded for at least three days.  
EV treatment 
EV powder (ApexBio Technology, TX, USA) was dissolved in dimethyl sulfoxide (DMSO, 
Sigma, MO, USA) and to constitute a 10mM stock solution.  EV was added in synchronized 
MCF-7 cell culture at indicated times (T0, T12 or T24) at a final concentration of 1µM and an 
equivalent volume of DMSO was added in the control sample (CTRL). The cells were 
collected for western-blot and cytometry analysis 24 h after EV exposure onset.  
Western-blot  
MCF-7 cells were washed once with PBS and lysed in 2X Laemmli buffer (100 mM Tris, pH 
6.8, 20% glycerol, 4% SDS, 0.05% bromophenol blue, and 10 mM DTT). The lysates were 
then boiled 5 minutes and subjected to sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) gel. After transfer, nitrocellulose membranes were blotted with 
the following antibodies: Anti-Actin (A3854, Sigma, MO, USA); Anti-HSC70 (SPA-815, 
Stressgen, CA, USA); Anti-Cyclin D1 (556470, BD Bioscience, NJ, USA); anti-Bmal1 
(ab3350), anti-Cry2 (ab38872) and anti-Per2 (ab179813) were from ABCAM (Cambridge, 
UK); Anti-Rev-ERB α (#13418), Anti-Phospho-S6 ribosomal protein (Ser240/244) (#5456), 
Anti-S6 ribosomal protein (#2317), Anti-Cyclin D3 (#2936), Anti-P21 Waf1/Cip1 (#2947) 
were from Cell Signaling Technology(MA, USA). Primary antibodies were detected with 
appropriate secondary antibodies conjugated with horseradish peroxidase and the membranes 
were developed with an enhanced chemiluminescence (ECL) system (ECL detection kit, 
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Thermofisher, MA, USA). The results were quantified by Image J, Actin or HSC70 was used 
as control for protein loading. 
Quantitative real time PCR (qRT-PCR) 
Cells were collected at indicated times, then total RNA was extracted as previously 
described.
24-25 
Reverse transcription was performed with Superscript II RT-kit (Invitrogen, 
CA, USA). Quantitative real time PCR was performed with LightCycler 480 using 
LightCycler 480 SYBR Green I master kit (Roche, Bâle, Switzerland). Primers used for gene 
amplification were previously described.
25
 Primers for Bmal1 were as following, Fwd: 
AAGGATGGCTGTTCAGCACATGA; Rev: CAAAAATCCATCTGCTGCCCTG. Primers 
for 36B4 were as following, Fwd: AATCCCTGACGCACCGCCGTGATG, Rev:  
TGGGTTGTTTTCCAGGTGCCCTCG. Hybridization temperature for all primers was 60°C. 
The relative quantification of target RNA by using 36B4 as a reference was computed with 
the Relquant software (Roche, Bâle, Switzerland), which is based on the 2(–ΔΔT) method. 
Flow cytometry analysis 
Cells were trypsinized by Trypsin-EDTA (ThermoFisher, MA, USA), then fixed with ice-cold 
70% ethanol and afterwards washed twice in ice-cold PBS with centrifugation at 300g for 10 
minutes. The cells were then incubated with anti-Phospho-S6-APC (#14733) (Cell Signaling, 
MA, USA) and anti-Ki67-FITC (BD Biosciences, NJ, USA) in a PBS solution containing 
0.5% BSA and 2mM EDTA for 30 min at 4°C. After being washed once with PBS, cells were 
suspended in PBS containing 50ug/ml propidium iodide (PI) and 20ug/ml RNaseA (Sigma, 
MO, USA) and incubated overnight at 4°C. A LSR Fortessa™ cell analyzer (BeTon 
Dickinson, NJ, USA) was used for flow cytometry analysis.  
Generation of bioluminescence reporter cell lines and bioluminescence imaging 
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The lentiviral circadian bioluminescence reporter constructs pLV7-Bsd-p(Bmal1)-dLuc 
(p(Bmal1)-dLuc) was a kind gift of A.C Liu.
26
 Lenti-viral particles were produced by transient 
transfection with TransIT-LT (Mirus-Bio, WI, USA) in HEK293FT cells (Thermo Fisher, 
Paisley, UK) according to the manufacturer’s instructions. pWPI (Addgene plasmid# 12254, 
MA, USA) was used as transfection control. For target cell transduction, a 10 cm dish of 50% 
confluent MCF-7 or MCF-10A cells were incubated with 1ml filtered viral supernatant in the 
presence of 8µg/ml polybrene (SIGMA, MO, USA) for 6 hours. Three days after viral 
transduction, infected cells were selected by adding Blasticidin (2.5µg/ml to MCF-7 and 
6µg/ml to MCF-10A) to the culture medium for at least 1 week.  
The LumiCycle (Actimetrics, IL, US) luminometer was used for bioluminescence recording 
of serum shocked MCF-7 p(Bmal1)-dLuc and MCF-10A p(Bmal1)-dLuc cells in 35 mm 
dishes at 37°C with 5% CO2. The bioluminescence signal was recorded every 10 min for at 
least 3 days. The LumiCycle Analysis program was used to obtain baseline-subtracted data.  
Statistical analysis 
For flow cytometry analysis, statistically significant differences were determined by two-way 
ANOVA or by t-test by using GraphPad Prism version 6.0. Error bars represent standard error 
of the mean (SEM) or standard deviation (SD) of independent experiments. For western-blot 
or qRT-PCR, time-dependent differences were first statistically validated with one-way 
ANOVA. If the time-dependent differences is significant, the results were then analyzed by 
Cosinor algorithm based on Fourier transformed analysis for sinusoidal function using SPSS 
to determine if the variation corresponds to a sinusoidal waveform over the circadian period. 
The Cosinor analysis provided the following parameters estimates: mesor (rhythm-adjusted 
mean), amplitude (difference between mesor and maximum of best-fitting cosine function), 
and acrophase (time of maximum in best-fitting cosine function). These parameters are 
reported with their respective 95% confidence limits. For bioluminescence recording, the 
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circadian period and the statistical significance of the computed period are determined by 
Periodogram analysis. 
Results 
mTOR activity displayed a rhythmic variation after serum shock 
An about 24 hours (24h) oscillatory pattern in phosphorylated S6 ribosome protein was found 
in MCF-7 cell populations after serum shock (Figure 1A and 1B). As one of the main mTOR 
effectors, Ribosomal protein S6 phosphorylation level was used as a proxy for mTOR 
activity.
8-9
 In three independent experiments, phosphorylated S6 ribosome protein gradually 
increased from T8, reached a peak between T12 to T20, then decreased toward a nadir around 
T24 to T28, and rose again at T36 (Figure 1B). Time-dependent differences were statistically 
validated with one-way ANOVA (p=0.03). A statistically significant 24h oscillation in 
phosphorylated S6 ribosome protein was further suggested by Cosinor analysis (p=0.0002), 
with a double-amplitude of 38% ± 14% relative to the rhythm-adjusted mean (Mesor), and an 
Acrophase occurring at 16h27min ± 1h35min (Figure 1C). However, no apparent time 
dependent differences were observed for total S6 protein expression (one-way ANOVA, NS; 
Cosinor, NS; Figure 1C). In contrast, unsynchronized MCF-7 cells did not show significant 
time-dependent differences in neither phosphorylated S6 nor total S6 protein expression (one-
way ANOVA, NS; Figure 1D and 1E) 
The oscillatory pattern in mTOR activity was consistent in every cell cycle phase  
The use of the tri-staining method (Ki67 antibody, PI and phosphorylated ribosomal protein 
S6 antibody) for cytometry analysis, enabled us to assess mTOR activity dynamics in distinct 
cell cycle phases (Figure 2A and 2B). A consistent oscillatory pattern in S6 phosphorylation 
level was found in G0/G1, S and G2/M phase cells that persisted for two consecutive 24h 
cycles after serum shock (Figure 2C). Higher phosphorylated S6 expression occurred at T12 
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and T36, in alternation with lower ones at T0, T24 and T48. Irrespective of sampling time, 
phosphorylated S6 levels were higher in S and G2/M phase cells compared to G0/G1 phase 
cells (Figure 2D). 
Lack of evident circadian oscillation of Bmal1 expression in serum shocked MCF-7 cells 
Previous study on Bmal1
-/-
 mice revealed the implication of Bmal1 in mTOR signaling 
regulation
11
; we therefore probed Bmal1 expression in serum shock MCF-7 cells to check if 
there existed one circadian oscillation pattern in Bmal1expression.  
First, real-time bioluminescence of MCF-7 p(Bmal1)-dLuc and MCF-10A p(Bmal1)-dLuc 
reporter cells were recorded over three days. MCF-10A p(Bmal1)-dLuc reporter cells which 
used as positive control displayed a statistically significant rhythm in Bmal1 promotor 
activation (p<0.05, Periodogram analysis, Figure 3A). However, MCF-7 p(Bmal1)-dLuc did 
not show one evident rhythm in Bmal1 gene expression (p>0.05, NS for three conditions, The 
circadian period and the statistical significance of the computed period are determined by 
Periodogram analysis, Figure 3A).  
The lack of detectable Bmal1 expression oscillation was confirmed in serum shocked MCF-7 
cells at mRNA and protein levels by qRT-PCR and western-blot respectively (Figure 3B-3C). 
One-way ANOVA ruled out statistically significant time dependent differences in Bmal1 
mRNA and protein expressions.  
Moreover, no obvious time related oscillatory pattern was found in both mRNA and protein 
expression of other clock genes (Per2, Rev-Erbα and Cry2) in serum shocked MCF-7 cells 
over 36 hours (data not shown). 
Serum shock induced rhythmic Cyclin D1 and pRB expressions and synchronized cell 
cycle in MCF-7 cells 
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Although no rhythmic mRNA and protein expression of the core circadian genes could be 
detected following a serum shock, Cyclin D1 and phosphorylated RB (pRB), two key G1 
phase proteins displayed oscillatory patterns, with a period around 24h (Figure 4A and 4B). 
Time-dependent differences were statistically validated with one-way ANOVA (Cyclin D1, 
p= 0.0003; pRB, p=0.04). Cosinor analysis further validated a 24h period (Cyclin D1, 
p=0.0062; pRB, p=0.0017 Figure 1C) and revealed a double-amplitude of 62% ± 34% 
relative to mesor and an acrophase occurred at 18h10 min ± 2 h 15 min for Cyclin D1; for the 
pRB protein rhythm, the double-amplitude relative to mesor is 44% ± 18% and the acrophase 
was located at 18h32 min ± 1h56 min (Figure 1C). The 24h oscillation in Cyclin D1 and pRB 
expressions indicated that serum shock induced cell cycle synchronization. Cytometry 
analysis further confirmed that an accumulation of cells in G1/G0 phase at T0 which then 
released into S at T24 (Figure 4C). 
Everolimus inhibited MCF-7 cells proliferation without inducing apoptosis  
Using phosphorylated S6 antibody and PI double labelling flow cytometry, similar dose-
response curves of EV on the inhibition of S6 phosphorylation were found in every cycle 
phase of MCF-7 cells.  A steeper slope of the dose-response relation was shown in S and 
G2/M phase cells (Figure 5A). Maximum inhibition was reached at 1µM EV and plateaued 
thereafter, since a similar effect was found with 10µM EV. Such dose-dependency was 
further confirmed by western-blot analysis for phosphorylated S6 protein level irrespective of 
cell cycle phase (Figure 5B). Therefore, an EV concentration of 1µM was selected for further 
experiments. 
First, we investigated EV induced apoptosis and cell cycle arrest 48h after exposure onset. EV 
did not increase the proportion of apoptotic or dead cells compared to controls, as assessed 
with Annexin V positive cells or Annexin V and PI double positive cells, respectively (Figure 
5C). However, EV inhibited MCF-7 cells proliferation, as indicated by a significant increase 
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in G0/G1 phase and decrease in G2/M phase cells (Figure 5D). Thus, G0/G1 phase blockage 
was used as the main endpoint when assessing anti-proliferative effects of EV according to 
drug timing. 
Time dependent anti-proliferative effect of EV in serum shocked MCF-7 cells. 
In order to imitate different clinical dosing time (one time every day, morning or evening), 
serum shocked MCF-7 cells were exposed to EV for 24h under three different time schedules: 
T0 to T24, T12 to T36 or T24 to T48 respectively. G0/G1 blockage was used to determine EV 
anti-proliferative effect (Figure 6A). EV exposure from T0 to T24 or exposure from T24 to 
T48 induced a more evident G0/G1 blockage compared to EV exposure from T12 to T36 in 
serum shocked MCF-7 cells (Figure 6B and 6C). In matching up to the control, EV exposure 
from T0 to T24 and from T24 to T48 increased respectively 27.5%±5.5% and 17.3%±3.6% 
G0/G1 phase cells. However, G0/G1 phase cell is only increased 7.19%±2.5% when MCF-7 
cell was treated from T12 to T36. The time dependent efficacy of EV in serum shocked MCF-
7 cells is statistically validated for T0-T24 VS T12-T36 (p=0.0022) and T24-T48 VS T12-
T36 (p=0.0186). However, there is no significant difference for T0-T24 VS T24-T48. (Figure 
6C).  
The increase in the proportion of G0/G1 phase cells matched significant decreases in both S 
and G2/M phase cells when EV dosing is started at T0 or T24. However, EV exposure 
starting at T12 did not significantly reduce the proportion of S or G2/M cells compared to 
controls (Figure 6B). Hence, the blockage efficacy was largely higher following drug 
exposure at either T0-T24 or T24-T48 compared to T12-T36.   
The cytometry and western-blot analysis revealed that after a 24h incubation with 1uM EV, 
S6 phosphorylation was strongly inhibited in the three different conditions (T0-T24, T12-T36 
or T24-T48). (Figure 6D-6E). 
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EV inhibited Cyclin D1 and Cyclin D3 expressions as well as RB phosphorylation 
Western-blot analysis revealed that inhibition of mTOR activity by EV further decreased 
Cyclin D1 and Cyclin D3 protein levels (Figure 7A-7B). Importantly, inhibition of mTOR by 
EV did not decrease RB expression but only its phosphorylation. As Cyclin D and 
phosphorylated RB (pRB) play an essential role in G1 phase progression, EV induced 
diminution of Cyclin D and pRB provided a potential explanation of the G0/G1 arrest induced 
by EV. 
Discussion: 
Here we tried to understand how and why the administration time of Everolimus could affect 
its anti-proliferation efficacy by using ER
+
 breast cancer cell line MCF-7 as a model.  
We found that mTOR activity, the target enzyme of EV, displayed a 24h rhythmic pattern in 
serum shocked MCF-7 cells. EV dose dependently arrested MCF-7 cells in G0/G1 phase 
without eliciting detectable apoptosis. This result was consistent with previous results 
suggesting that several pan-mTOR inhibitors induced also cell cycle arrest but not cell 
death.
27
 Interestingly, the extent of EV induced G0/G1 blockage varied significantly 
according to EV administration time in the serum shocked MCF-7 cells. Normally, serum 
shock is used to synchronize both the cell cycle and the circadian clock, two essential 
biological oscillators which are all around 24h.
28-29
 Especially, these two process share some 
common elements in biochemical and molecular regulation, like hormones, growth factor, E-
box and bHLH transcription factors and can be reset by light or serum response, etc..
23, 28
 The 
conservation of essential elements for the molecular regulation of circadian and cell cycle 
underlies similarities in the dedicated molecular mechanisms, which allow both the ordered 
progression along cell cycle and the maintenance of circadian rhythm. Recent studies revealed 
also possible molecular interaction between the endogenous circadian clock and cell cycle.
30-
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34
 However, circadian rhythms are often altered in breast cancer patients
35-37 
as well as in 
breast tumors and breast cancer cells lines.
22, 38-42
 Alterations and desynchronization of 
molecular clock machinery on genetic and epigenetic level were observed in more aggressive 
breast cancer and those lacking estrogen receptor.
 
Numerous studies have suggested that there 
are no mRNA circadian-like oscillations of canonical circadian genes in many breast cancer 
cell lines, either in ER
+
 cells (such as MCF-7 or T47D) or in ER
-
 cells (such as HS578T and 
MDA-MB231). However, cultured human mammary epithelial cells maintain an inner 
circadian clocks.
22, 41-42 
Using luciferase reporter technology, our results revealed also serum 
shock induced the rhythmical expression of Bmal1 promotor in non-tumorigenic epithelial 
cell line MCF-10A, supporting it was endowed with functional circadian clocks. But ER
+
 
MCF-7 cell did not display an evident circadian oscillations of core clock genes expression 
under the examination of luciferase reporter technology, qRT-PCR and western-blot. 
However, after a serum shock, MCF-7 cell exhibited surprisingly a rhythmic pattern of mTOR 
activity as well as a synchronized cell cycling and a significant 24h rhythms in G1 phase 
progression proteins, such as Cyclin D1 and phosphorylated RB.  
Increasing mTOR activity was shown to drive cell cycle progression and increase cell 
proliferation mainly thanks to its effect on protein synthesis. Indeed, it was reported that 
mTOR activity regulated Cyclin D1 translation through phosphorylating S6 kinase or 4E-
BP1.
43-44 
Similarly, Rapamycin, an EV analog, decelerated the accumulation of Cyclin D1 
during p21 induced cell cycle arrest.
45
 Our results revealed mTOR inhibition by EV could 
decrease Cyclin D1 and Cyclin D3 protein expression, but not alter P21 expression. 
Interestingly, the mTOR activity peak started at T12, slightly before the Cyclin D1 expression 
peak (T16), suggesting that induction of Cyclin D1 expression after mTOR activation takes 
several hours. Usually, Cyclin D-Cdk4/6 dimer phosphorylates RB protein in G1 phase cell, 
which releases transcription factor E2F from phosphorylated Rb and become active to drive 
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G1 to S phase transition. As RB is one of the main substrates of Cyclin D-Cdk4/6 dimer, it is 
reasonable that Cyclin D1 expression and RB phosphorylation presented a similar oscillation 
tendency and arrive to their peak at the same time. Moreover, EV induced only a decreased 
RB phosphorylation level but not total RB expression, which suggested that mTOR is not 
directly involved in RB expression. The decreased RB phosphorylation could be due to the 
diminution of Cyclin D expression. Taken together, our results suggested that the oscillation 
of mTOR activity might induce the oscillation of expression or phosphorylation of some G1 
progression proteins, which in turn could couple it to cell cycle progression. In view of the 
rhythmic activation of mTOR, when EV was added at different times on serum shocked 
MCF-7 cells which had different mTOR activity level, different G1 progression proteins 
levels and therefore different cell cycle progression probabilities, it was reasonable the cells 
presented varied EV sensitivity. 
The optimal cancers therapy should be to minimize the toxicity of drug to the host but 
maximize its effect on the tumor. But unfortunately, in most cancers the clinicians have to 
apply higher toxicity to gain good efficacy. Based on our results and a growing literature on 
chronotherapy,
18-20
 drug dosing timing has the potential to become a critical factor, but 
currently its importance is underestimated. Chronotherapy aims to design optimal drug dosing 
schedules based on physiological circadian rhythms, which could increase its efficacy and 
reduce its toxicity.
16-18
 The in vitro MCF-7 model investigated here provides useful hints 
toward EV chronotherapy in human ER
+
 breast cancer. A striking finding was that chrono-
efficacy of EV seemed not require canonical circadian rhythm of core molecular clocks. 
Moreover, exogenous signals to synchronize the molecular clocks also coordinate and couple 
rhythmic mTOR activity and cell cycling with about 24h periods. These results suggested the 
potential importance of clock gene independent rhythms in chronotherapy. Clock gene 
independent rhythms appear pervasively in biology, as shown with the highly conserved 
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Peroxiredoxins biochemical circadian clock, and the cell autonomous 12h clock in mouse 
liver, which coordinated ER and mitochondrial functions independently from the genetic 
circadian clock.
46-47 
Even in MCF-7 cells who did not possess one net clock gene rhythm, the 
serum shock could still induce rhythmic mRNA expressions of more than 400 genes.
41
 Thus, 
in chronotherapy, how to take into account not only clock gene dependent rhythms but also 
clock gene independent rhythms will be a new potential clue for the future. Remarkably, the 
xenografting of MCF-7 cells into nude rats could re-establish a circadian pattern in Bmal1 
transcription, suggesting that the importance of host circadian time cues in the circadian 
coordination of cancer cells in vivo.
42
 Thus, if it is possible to re-establish cancer cell’s 
rhythm by reinforcing the breast cancer patients’ rhythms which are often deregulated during 
cancer progression, how to take in consideration the interaction between cancer cells and 
health host cells also need to be considered for jointly optimizing EV chronotherapy effects.  
The chrono-efficacy of EV found here provided a new perspective for cancer chronotherapy, 
which could be potentially applied to other anticancer agents.  
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Legends of figures 
Figure 1: Circadian rhythm in mTOR activity after serum shock  
A and B): Western-blot revealed a rhythmic change of mTOR activity in MCF-7 cell after 
serum shock (3 independent experiments). MCF-7 cells were harvested every 4h after serum 
shock for 36h. The first time point (T0) was taken just after the serum shock. The 
phosphorylation level of S6 was used to evaluate mTOR activity. Actin was used as a control 
of protein loading to calculate phosphorylated S6 and total S6 level at every T time. 
C): The table resumed Cosinor analysis which revealed a statistically significant 24h 
oscillation in phosphorylated S6 ribosome protein, Cyclin D1 and phosphorylated RB protein, 
but not in S6 protein.  
D and E): Western-blot showed mTOR activity in MCF-7 cell without synchronization (3 
independent experiments). The non-synchronized MCF-7 cells were harvested every 4h for 
36h as the synchronized MCF-7 cells. Actin was used as a control of protein loading to 
calculate phosphorylated S6 and total S6 level at every T time. 
Figure 2: The oscillatory pattern in mTOR activity was consistent in every cell cycle 
phase  
A and B): The combination of anti-piS6-APC, Ki67-FITC and PI in cytometry analysis 
allowed to determine mTOR activity of cells in different cell cycle phases. The combination 
of Ki67 and PI allowed to determine cell cycle phase distribution and mTOR activity is 
indicated by phosphorylated S6 level.  
C): Cytometry analysis revealed an oscillatory pattern of mTOR activity in every cell cycle 
phase of MCF-7 cell. The first time point (T0) was taken just after the serum shock. Cells 
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were then harvested at indicated times after synchronization. The Phospho-S6-APC level of 
every cell cycle phase (G0/G1, S, G2/M) at every T time (T0, T12, T24, T36 and T48) was 
calculated from 6 independent experiments.  
D): The cells in S and G2/M phases presented one higher S6 phosphorylation levels compared 
to cells in G0/G1 phase at each sampling time T.  
Figure 3: Lack of evident circadian oscillation of Bmal1 expression in serum shocked 
MCF-7 cells  
A): Average real-time bioluminescence traces of serum shocked MCF-7 p(Bmal1)-dLuc or 
MCF-10A p(Bmal1)-dLuc reporter cell lines. Three different cell confluences were used at 
the beginning of record, condition (1) was around 10-15%, condition (2) was around 20-25% 
and condition (3) was around 30-40%. The plotted data represent bioluminescence (photon 
count/sec) against time (hours). For details see Material and Methods. The circadian period 
and the statistical significance of the computed period are determined by Periodogram 
analysis. MCF-10A p(Bmal1)-dLuc reporter cells presented one significant rhythm of Bmal1 
promotor activation, condition: (1) p<0.048, Period =20.5h; (2) p<0.048, Period=21.5h; (3) 
P<0.0005, Period=21.7h. However, MCF-7 p(Bmal1)-dLuc cells did not show any consistent 
oscillation in Bmal1 expression (p>0.05, NS for every confluence condition). 
B): Western-blot analysis did not revealed an obvious oscillation in Bmal1 protein expression 
oscillation in serum shocked MCF-7 cells. Bmal1 protein expression was analyzed every 4h 
after serum shock for 36h. Actin was used as a control of protein loading.  
C): qRT-PCR analysis revealed that MCF-7 cells did not display an obvious rhythm in Bmal 
RNA expression. Bmal1 RNA expression was analyzed every 4h after serum shock for 36h. 
36B4 was used as reference for relative quantification of target gene mRNA.  
Figure 4: Serum shock induced Cyclin D1 and pRB rhythmic oscillations and 
synchronized cell cycle in MCF-7 cells 
A and B): Western-blot revealed the rhythmic expression of Cyclin D1 and phosphorylated 
RB in serum shocked MCF-7 cell. MCF-7 cells were harvested every 4h after serum shock for 
36h. The first time point (T0) was taken just after the serum shock. Actin and HSC70 were 
used as protein loading control to calculate Cyclin D1 and phosphorylated RB expression 
level at every T time (3 or 4 independent experiments). HSC70 was used as a control of 
protein loading to calculate pRB, Cyclin D1 and Cyclin D3 expression level at every T time. 
C): Cytometry analysis revealed that an accumulation of cells in G1/G0 phase at T0 induced 
by serum shock which then released into S at T24. 
Figure 5: EV inhibited MCF-7 cells proliferation without inducing apoptosis  
A): Flow cytometry analysis revealed dose-dependent inhibition of S6 phosphorylation level 
in different cell cycle population.  
B): Western-blot result revealed dose-dependent inhibition of S6 phosphorylation level by 
EV. 
C): Annexin V and PI analysis by cytometry revealed that EV did not induce apoptosis or cell 
death of MCF-7 cells.  
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D): Ki67 and PI analysis by cytometry showed that EV inhibited MCF-7 cells proliferation 
and induced a significant increase of G0/G1 and G2/M phases cells after 48h incubation 
Figure 6: Time-dependent anti-proliferative effect of EV in serum shocked MCF-7 cells. 
A): After serum shock, cell cycles of EV treated MCF-7 cells and their controls under three 
different time schedules (T0-T24, T12-T36 or T24-T48) were analyzed by cytometry.  
B): Graphical resumed from cell cycle cytometry analysis illustrated the different cell cycle 
phase distributions of T0-T24, T12-T36 or T24-T48 EV treated serum shocked MCF-7 cells 
compared to their control (5 independent experiments). The whiskers go down to the smallest 
value and up to the largest, the line in the box is plotted at the median.  
C): Histograms depicting the relative changes in cell cycle phase distributions according to 
EV timing schedule. In matching up to the control, the proportion of G0/G1 phase cells were 
increased much more evident when EV exposure from T0 to T24 or from T24 to T48 in 
comparison with EV exposure from T12 to T36.   
D): Graphic resumed from the cytometry analysis revealed S6 phosphorylation level was 
inhibited by EV with different dosing times in serum shocked MCF-7 cell.  
E): Western-blot results showed S6 phosphorylation level was inhibited by EV with different 
dosing times in serum shocked MCF-7 cell.  
Figure 7: EV inhibited Cyclin D1 and Cyclin D3 expression as well as RB 
phosphorylation 
A): Western-blot results show that different 24h exposure schedules of EV inhibit the protein 
expression of phosphorylated RB, Cyclin D1, and Cyclin D3, but not of total RB and P21.  
Actin was used as protein loading control to calculate RB, pRB, Cyclin D1 and Cyclin D3 
expression levels. 
B): Three independent western-blot results were quantified by Image J. Statistical analysis (T-
test) revealed that EV induced significant diminution of Cyclin D1, Cyclin D3 and RB 
phosphorylation level but not the total RB expression level. 
 
 
 
 







